VCRE
Vicore Pharma Holding AB
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$9.80
−3.92%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -52.8%
- EBITDA
- +104.1%
- EPS
- +5.1%
Three-year CAGR
- Revenue
- -96.5%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- -100.0%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026